Back to Journals » Patient Preference and Adherence » Volume 10

Drugs under preclinical and clinical study for treatment of acute and chronic lymphoblastic leukemia

Authors Jacob JA, Salmani JMM, Chen B

Received 29 March 2016

Accepted for publication 3 May 2016

Published 20 June 2016 Volume 2016:10 Pages 1115—1119

DOI https://doi.org/10.2147/PPA.S109477

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Naifeng Liu

Joe Antony Jacob, Jumah Masoud Mohammad Salmani, Baoan Chen

Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People’s Republic of China

Abstract: Targeted therapy has modernized the treatment of both chronic and acute lymphoblastic leukemia. The introduction of monoclonal antibodies and combinational drugs has increased the survival rate of patients. Preclinical studies with various agents have resulted in positive outputs with Phase III trial drugs and monoclonal antibodies entering clinical trials. Most of the monoclonal antibodies target the CD20 and CD22 receptors. This has led to the approval of a few of these drugs by the US Food and Drug Administration. This review focuses on the drugs under preclinical and clinical study in the ongoing efforts for treatment of acute and chronic lymphoblastic leukemia.

Keywords: targeted therapy, monoclonal antibodies, preclinical studies, receptors, lymphoblastic leukemia
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Tf-PEG-PLL-PLGA nanoparticles enhanced chemosensitivity for hypoxia-responsive tumor cells

Liu P, Zhang H, Wu X, Guo L, Wang F, Xia G, Chen B, Yin H, Wang Y, Li X

OncoTargets and Therapy 2016, 9:5049-5059

Published Date: 12 August 2016

Lobaplatin for the treatment of SK-MES-1 lung squamous cell line in vitro and in vivo

Zhang H, Chen R, Yang S, Liu W, Li K, Zhang H, Zhu X, Chen B

OncoTargets and Therapy 2016, 9:4215-4224

Published Date: 11 July 2016

Advances of wogonin, an extract from Scutellaria baicalensis, for the treatment of multiple tumors

Wu X, Zhang H, Salmani JMM, Fu R, Chen B

OncoTargets and Therapy 2016, 9:2935-2943

Published Date: 17 May 2016

Targeted multidrug-resistance reversal in tumor based on PEG-PLL-PLGA polymer nano drug delivery system

Guo L, Zhang H, Wang F, Liu P, Wang Y, Xia G, Liu R, Li X, Yin H, Jiang H, Chen B

International Journal of Nanomedicine 2015, 10:4535-4547

Published Date: 16 July 2015

Synthesis and characterization of tumor-targeted copolymer nanocarrier modified by transferrin

Liu R, Wang Y, Li X, Bao W, Xia G, Chen W, Cheng J, Xu Y, Guo L, Chen B

Drug Design, Development and Therapy 2015, 9:2705-2719

Published Date: 22 May 2015

Primary malignant lymphoma of the uterus and broad ligament: a case report and review of literature

Chen R, Yu Z, Zhang H, Ding J, Chen B

OncoTargets and Therapy 2015, 8:265-268

Published Date: 29 January 2015

PLGA-PLL-PEG-Tf-based targeted nanoparticles drug delivery system enhance antitumor efficacy via intrinsic apoptosis pathway

Bao W, Liu R, Wang YL, Wang F, Xia GH, Zhang HJ, Li XM, Yin HX, Chen BA

International Journal of Nanomedicine 2015, 10:557-566

Published Date: 12 January 2015

Apoptosis selectively induced in BEL-7402 cells by folic acid-modified magnetic nanoparticles combined with 100 Hz magnetic field

Wen J, Jiang S, Chen Z, Zhao W, Yi Y, Yang R, Chen B

International Journal of Nanomedicine 2014, 9:2043-2050

Published Date: 23 April 2014

Clinical outcomes of transfusion-associated iron overload in patients with refractory chronic anemia

Gao C, Li L, Chen BA, Song HH, Cheng J, Zhang XP, Sun YY

Patient Preference and Adherence 2014, 8:513-517

Published Date: 22 April 2014